Alpha-tocopherol inhibits TNF alpha release from activated human monocytes

K. Marangon, S. Devaraj, I. Jialal

Research output: Contribution to journalArticle

Abstract

Several inflammatory mechanisms contribute to atherogenesis. Monocytes (Mo) are crucial cells in the artery wall that produce proatherogenic cytokines such as interleukin-1B and tumor necrosis factor alpha (TNF). Recently, we showed that supplementation with alpha-tocopherol (AT) significantly decreases the release of interleukin-1B from human Mo. The aim of this study was to test the effect of AT on the release of TNF. Human Mo were isolated from 21 subjects at baseline and follow ing AT supplementation (1200 IU/day for 8 wks). AT produced a significant reduction in TNF release from activated Mo (baseline: 14.2±7.67 pg/mg protein vs. supplemented: 4.9±4.65 pg/mg protein, p<0.001). To examine mechanisms by which AT inhibits TNF, we tested the effect of AT (100uM) on protein kinase C (PKC). AT significantly inhibited PKC levels from human Mo and the PKC inhibitor, Calphostin C, had no effect on TNF release from activated Mo. Leukotriene B4 (LTB4), a product of 5-lipoxygenase (5-LO), augments cytokine release from Mo. AT significantly inhibited 5-LO from Mo and the 5-LO inhibitor, MK886, significantly inhibited TNF release from activated Mo. Addition of LTB4 to the system partially resurrected TNF activity to that of activated cells (LPS: 6.9± 1.5 pg/mg protein; LPS+MK886: 1.6±1.2 pg/mg protein; LPS+ MK886+LTB4: 3.4±1.7 pg/mg protein). Thus, in activated human monocytes, AT inhibits TNF release partly by inhibition of 5-LO and other mechanisms are being studied.

Original languageEnglish (US)
JournalFASEB Journal
Volume12
Issue number5
StatePublished - Mar 20 1998
Externally publishedYes

Fingerprint

alpha-Tocopherol
monocytes
alpha-tocopherol
tumor necrosis factor-alpha
Monocytes
Tumor Necrosis Factor-alpha
Arachidonate 5-Lipoxygenase
lipoxygenase
Leukotriene B4
leukotrienes
protein kinase C
Protein Kinase C
Interleukins
Proteins
interleukins
proteins
cytokines
Cytokines
Lipoxygenase Inhibitors
atherogenesis

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Marangon, K., Devaraj, S., & Jialal, I. (1998). Alpha-tocopherol inhibits TNF alpha release from activated human monocytes. FASEB Journal, 12(5).

Alpha-tocopherol inhibits TNF alpha release from activated human monocytes. / Marangon, K.; Devaraj, S.; Jialal, I.

In: FASEB Journal, Vol. 12, No. 5, 20.03.1998.

Research output: Contribution to journalArticle

Marangon, K, Devaraj, S & Jialal, I 1998, 'Alpha-tocopherol inhibits TNF alpha release from activated human monocytes', FASEB Journal, vol. 12, no. 5.
Marangon, K. ; Devaraj, S. ; Jialal, I. / Alpha-tocopherol inhibits TNF alpha release from activated human monocytes. In: FASEB Journal. 1998 ; Vol. 12, No. 5.
@article{ac804a2eb64b437783b0c3f7ca6fcfb8,
title = "Alpha-tocopherol inhibits TNF alpha release from activated human monocytes",
abstract = "Several inflammatory mechanisms contribute to atherogenesis. Monocytes (Mo) are crucial cells in the artery wall that produce proatherogenic cytokines such as interleukin-1B and tumor necrosis factor alpha (TNF). Recently, we showed that supplementation with alpha-tocopherol (AT) significantly decreases the release of interleukin-1B from human Mo. The aim of this study was to test the effect of AT on the release of TNF. Human Mo were isolated from 21 subjects at baseline and follow ing AT supplementation (1200 IU/day for 8 wks). AT produced a significant reduction in TNF release from activated Mo (baseline: 14.2±7.67 pg/mg protein vs. supplemented: 4.9±4.65 pg/mg protein, p<0.001). To examine mechanisms by which AT inhibits TNF, we tested the effect of AT (100uM) on protein kinase C (PKC). AT significantly inhibited PKC levels from human Mo and the PKC inhibitor, Calphostin C, had no effect on TNF release from activated Mo. Leukotriene B4 (LTB4), a product of 5-lipoxygenase (5-LO), augments cytokine release from Mo. AT significantly inhibited 5-LO from Mo and the 5-LO inhibitor, MK886, significantly inhibited TNF release from activated Mo. Addition of LTB4 to the system partially resurrected TNF activity to that of activated cells (LPS: 6.9± 1.5 pg/mg protein; LPS+MK886: 1.6±1.2 pg/mg protein; LPS+ MK886+LTB4: 3.4±1.7 pg/mg protein). Thus, in activated human monocytes, AT inhibits TNF release partly by inhibition of 5-LO and other mechanisms are being studied.",
author = "K. Marangon and S. Devaraj and I. Jialal",
year = "1998",
month = "3",
day = "20",
language = "English (US)",
volume = "12",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "5",

}

TY - JOUR

T1 - Alpha-tocopherol inhibits TNF alpha release from activated human monocytes

AU - Marangon, K.

AU - Devaraj, S.

AU - Jialal, I.

PY - 1998/3/20

Y1 - 1998/3/20

N2 - Several inflammatory mechanisms contribute to atherogenesis. Monocytes (Mo) are crucial cells in the artery wall that produce proatherogenic cytokines such as interleukin-1B and tumor necrosis factor alpha (TNF). Recently, we showed that supplementation with alpha-tocopherol (AT) significantly decreases the release of interleukin-1B from human Mo. The aim of this study was to test the effect of AT on the release of TNF. Human Mo were isolated from 21 subjects at baseline and follow ing AT supplementation (1200 IU/day for 8 wks). AT produced a significant reduction in TNF release from activated Mo (baseline: 14.2±7.67 pg/mg protein vs. supplemented: 4.9±4.65 pg/mg protein, p<0.001). To examine mechanisms by which AT inhibits TNF, we tested the effect of AT (100uM) on protein kinase C (PKC). AT significantly inhibited PKC levels from human Mo and the PKC inhibitor, Calphostin C, had no effect on TNF release from activated Mo. Leukotriene B4 (LTB4), a product of 5-lipoxygenase (5-LO), augments cytokine release from Mo. AT significantly inhibited 5-LO from Mo and the 5-LO inhibitor, MK886, significantly inhibited TNF release from activated Mo. Addition of LTB4 to the system partially resurrected TNF activity to that of activated cells (LPS: 6.9± 1.5 pg/mg protein; LPS+MK886: 1.6±1.2 pg/mg protein; LPS+ MK886+LTB4: 3.4±1.7 pg/mg protein). Thus, in activated human monocytes, AT inhibits TNF release partly by inhibition of 5-LO and other mechanisms are being studied.

AB - Several inflammatory mechanisms contribute to atherogenesis. Monocytes (Mo) are crucial cells in the artery wall that produce proatherogenic cytokines such as interleukin-1B and tumor necrosis factor alpha (TNF). Recently, we showed that supplementation with alpha-tocopherol (AT) significantly decreases the release of interleukin-1B from human Mo. The aim of this study was to test the effect of AT on the release of TNF. Human Mo were isolated from 21 subjects at baseline and follow ing AT supplementation (1200 IU/day for 8 wks). AT produced a significant reduction in TNF release from activated Mo (baseline: 14.2±7.67 pg/mg protein vs. supplemented: 4.9±4.65 pg/mg protein, p<0.001). To examine mechanisms by which AT inhibits TNF, we tested the effect of AT (100uM) on protein kinase C (PKC). AT significantly inhibited PKC levels from human Mo and the PKC inhibitor, Calphostin C, had no effect on TNF release from activated Mo. Leukotriene B4 (LTB4), a product of 5-lipoxygenase (5-LO), augments cytokine release from Mo. AT significantly inhibited 5-LO from Mo and the 5-LO inhibitor, MK886, significantly inhibited TNF release from activated Mo. Addition of LTB4 to the system partially resurrected TNF activity to that of activated cells (LPS: 6.9± 1.5 pg/mg protein; LPS+MK886: 1.6±1.2 pg/mg protein; LPS+ MK886+LTB4: 3.4±1.7 pg/mg protein). Thus, in activated human monocytes, AT inhibits TNF release partly by inhibition of 5-LO and other mechanisms are being studied.

UR - http://www.scopus.com/inward/record.url?scp=33749301311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749301311&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749301311

VL - 12

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 5

ER -